|
|
830 Winter Street
Waltham, MA 02451-1477 USA
phone:781-895-0600
fax:781-895-0611
|
|
| Symbol |
IMGN |
| Exchange |
Nasdaq |
| Founded |
1981 |
| Employees |
117 |
|
|
| www.immunogen.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Anticancer therapeutics |
|
| Management |
| Daniel M. Junius, President and Chief Executive Officer; John M. Lambert, Ph.D., Executive Vice President, Research; Gregory Perry, Senior Vice President and Chief Financial Officer; Suzanne Cadden, Vice President, Regulatory & Quality; James O'Leary, MD, Vice President and Chief Medical Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| tumor-targeting, antibodies, trastuzumab, genentech, myeloma |
|
|
|
| Description |
|
ImmunoGen, Inc. develops targeted anticancer therapeutics using their expertise in cancer biology, engineered antibodies and highly potent cancer-cell killing agents. They have established expertise in the development and humanization of tumor-targeting antibodies by developing specialized cancer-cell killing agents to serve as payloads. Their payload agents are 1, 000-10, 000 times more potent than traditional chemotherapy agents. ImmunoGen also have developed engineered linkers that keep the payload firmly attached to the antibody while the whole therapy is circulating through the bloodstream and then release it once the therapy has reached and entered a cancer cell. |
|
| Products / Services |
ImmunoGen develops targeted anticancer therapeutics. The company develops its own products and also establishes partnerships around its proprietary technology to broaden its product opportunities and to provide an inflow of cash.
|
|
| Technology / Differentiation |
| They created our TAP technology to achieve more effective, better tolerated anticancer drugs. A TAP compound is designed to focus its activity on cancer cells ? to kill these cells while minimizing damage to healthy tissue. A TAP compound consists of: a monoclonal antibody that binds specifically to a target ? its antigen ? found on cancer cells with a potent cell-killing agent attached. The antibody serves to target the compound specifically to cancer cells and the cell-killing agent serves to kill the cancer cells. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
